Camille Nigri Cursino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Camille Nigri Cursino has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Sabrina Calil-Elias
Universidade Federal Fluminense
3 shared publications - Ariela Dutra Norberto de Oliveira
Universidade Federal Fluminense
2 shared publications - Dulce Helena Nunes Couto
Instituto Nacional de Câncer José Alencar Gomes da Silva
2 shared publications - Jessica Pronestino de Lima Moreira
Universidade Federal Fluminense
2 shared publications - Thaísa Amorim Nogueira
Universidade Federal Fluminense
2 shared publications - Vanessa Cristiane da Silva Ferreira
Universidade Federal Fluminense
2 shared publications
Latest Publications
- 17 September 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Prognostic factors associated with survival in patients with colorectal cancer treated with capecitabine: A cohort study
Introduction: Colorectal cancer is a major public health problem due to its high incidence and mortality rates worldwide. Various clinical and sociodemographic characteristics are intrinsically linked to this neoplasm and can have a significant influence on both survival estimates and the utilization of healthcare resources. Within this context, capecitabine has emerged as an oral antineoplastic agent used in the treatment of this type of cancer. Objective: The objective of this study was to evaluate the survival of patients diagnosed with colorectal cancer who initiated treatment with capecitabine. Method: This is a retrospective cohort study conducted at a cancer reference center in Rio de Janeiro, Brazil, based on data collected from medical records of patients treated between 2017 and 2019. Survival analysis was performed using the Kaplan-Meier method, and the Cox proportional hazards model was used to estimate hazard ratios (HRs). Results: For clinical progression-free survival (cPFS), the estimated event-free probability at 12 months was 72%, while for overall survival (OS) it was 83%. Staging and performance status were associated with a higher probability of death. For both cPFS and OS, stage IV disease was associated with an approximately 3-fold increase in risk, and poor performance status with an approximately 3-fold increase for cPFS and 4-fold for OS. Conclusion: The results obtained reinforce the importance of individualized assessments that consider clinical and functional parameters to define the most appropriate therapeutic strategy in patients selected for a capecitabine-containing regimen.
- 17 September 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Prognostic factors associated with survival in patients with colorectal cancer treated with capecitabine: A cohort study
Introduction: Colorectal cancer is a major public health problem due to its high incidence and mortality rates worldwide. Various clinical and sociodemographic characteristics are intrinsically linked to this neoplasm and can have a significant influence on both survival estimates and the utilization of healthcare resources. Within this context, capecitabine has emerged as an oral antineoplastic agent used in the treatment of this type of cancer. Objective: The objective of this study was to evaluate the survival of patients diagnosed with colorectal cancer who initiated treatment with capecitabine. Method: This is a retrospective cohort study conducted at a cancer reference center in Rio de Janeiro, Brazil, based on data collected from medical records of patients treated between 2017 and 2019. Survival analysis was performed using the Kaplan-Meier method, and the Cox proportional hazards model was used to estimate hazard ratios (HRs). Results: For clinical progression-free survival (cPFS), the estimated event-free probability at 12 months was 72%, while for overall survival (OS) it was 83%. Staging and performance status were associated with a higher probability of death. For both cPFS and OS, stage IV disease was associated with an approximately 3-fold increase in risk, and poor performance status with an approximately 3-fold increase for cPFS and 4-fold for OS. Conclusion: The results obtained reinforce the importance of individualized assessments that consider clinical and functional parameters to define the most appropriate therapeutic strategy in patients selected for a capecitabine-containing regimen.
- 27 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial
Introduction: Cancer poses a major challenge to global health, impacting individuals, communities and societies worldwide. A significant proportion of global morbidity and mortality from neoplasms is accounted for by gastrointestinal tumors, due to their high incidence and lethality. Capecitabine, an oral antineoplastic agent, has brought advances in treatment, but requires caution regarding adherence and adverse events. In this context, it is believed that pharmaceutical care can significantly contribute to optimizing therapy and promoting better clinical outcomes. Objective: The aim of this study is to assess the advantages of pharmaceutical care for patients with gastric cancer who are being treated with capecitabine. Methods: A multicentre, prospective, longitudinal study was conducted with patients with gastric cancer using capecitabine. Patients were randomised into two groups, namely control (pharmaceutical guidance) and intervention (pharmaceutical care). Sociodemographic, clinical, and therapeutic data were collected, and adverse events were identified, classified and analysed, with impacts such as dose suspension or reduction, emergencies, hospitalisations and use of additional drugs being considered. Quality of life was assessed before and after treatment. Results: Thirty-one patients were selected, 16 of whom were in the intervention group. This group completed more treatment cycles, although it had a higher number of adverse events, with less severity. All patients who received pharmaceutical care were adherent to their treatment. In contrast, patients who did not receive pharmaceutical care had more suspensions and dose reductions. They also had a significant worsening of overall functional capacity. In addition, their symptoms such as nausea, vomiting, and diarrhea were aggravated. In the intervention group, however, there was an improvement in these symptoms. Conclusion: The study highlights the importance of pharmaceutical care in capecitabine treatment, especially in the management of adverse events, treatment adherence and promotion of quality of life. Despite the small sample size, the results reinforce the role of the pharmacist in the care of these patients and indicate the need for further studies with larger samples.
- 27 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Pharmaceutical care in patients with gastric cancer treated with capecitabine: A randomized clinical trial
Introduction: Cancer poses a major challenge to global health, impacting individuals, communities and societies worldwide. A significant proportion of global morbidity and mortality from neoplasms is accounted for by gastrointestinal tumors, due to their high incidence and lethality. Capecitabine, an oral antineoplastic agent, has brought advances in treatment, but requires caution regarding adherence and adverse events. In this context, it is believed that pharmaceutical care can significantly contribute to optimizing therapy and promoting better clinical outcomes. Objective: The aim of this study is to assess the advantages of pharmaceutical care for patients with gastric cancer who are being treated with capecitabine. Methods: A multicentre, prospective, longitudinal study was conducted with patients with gastric cancer using capecitabine. Patients were randomised into two groups, namely control (pharmaceutical guidance) and intervention (pharmaceutical care). Sociodemographic, clinical, and therapeutic data were collected, and adverse events were identified, classified and analysed, with impacts such as dose suspension or reduction, emergencies, hospitalisations and use of additional drugs being considered. Quality of life was assessed before and after treatment. Results: Thirty-one patients were selected, 16 of whom were in the intervention group. This group completed more treatment cycles, although it had a higher number of adverse events, with less severity. All patients who received pharmaceutical care were adherent to their treatment. In contrast, patients who did not receive pharmaceutical care had more suspensions and dose reductions. They also had a significant worsening of overall functional capacity. In addition, their symptoms such as nausea, vomiting, and diarrhea were aggravated. In the intervention group, however, there was an improvement in these symptoms. Conclusion: The study highlights the importance of pharmaceutical care in capecitabine treatment, especially in the management of adverse events, treatment adherence and promotion of quality of life. Despite the small sample size, the results reinforce the role of the pharmacist in the care of these patients and indicate the need for further studies with larger samples.
- 6 November 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (12) , 1601-1608
Predictors of adverse drug reactions associated with ribavirin in direct‐acting antiviral therapies for chronic hepatitis C
Purpose: To identify factors associated with the development of adverse drug reactions (ADR) in ribavirin therapeutic regimens.Methods: A multicenter, prospective study was conducted in three public health hospitals in Rio de Janeiro between November 2015 and March 2018. Inclusion criteria were defined by patient follow‐up at pharmaceutical consultation at the time of drug dispensing as those who used sofosbuvir in combination with simeprevir, daclatasvir, and/or ribavirin. All patients were invited to participate in the study during the first interview. Adverse drug reactions were reported according to the treatment regimen and frequency of occurrence. Statistical analysis was used to compare adverse reactions between treatments and their associated factors.Results: A total of 405 patients were included in the study (mean age 59.6 ± 9.6 years); 61.0% were female, 88.1% were infected with genotype 1, and 65.4% were cirrhotic. The most prescribed treatment was the combination of sofosbuvir, daclatasvir, and ribavirin (55.3%). The majority of patients reported at least one ADR during treatment (83.2%), of which fatigue, anemia, and headache were the most common. Being female (OR = 1.86, [1.08‐3.20]) and use of ribavirin (OR: 2.39; 95% CI [1.38‐4.13]) were predictors for the development of ADR, which was also associated with development of anemia (OR: 10.28; 95% CI: [5.78‐18.30]). Treatment efficacy was 98.1%.Conclusions: Direct‐acting antiviral has been shown to be safe and effective. Therefore, use of ribavirin is questionable due to associated adverse reactions and similar efficacy to other treatments.
- 6 November 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (12) , 1601-1608
Predictors of adverse drug reactions associated with ribavirin in direct‐acting antiviral therapies for chronic hepatitis C
Purpose: To identify factors associated with the development of adverse drug reactions (ADR) in ribavirin therapeutic regimens.Methods: A multicenter, prospective study was conducted in three public health hospitals in Rio de Janeiro between November 2015 and March 2018. Inclusion criteria were defined by patient follow‐up at pharmaceutical consultation at the time of drug dispensing as those who used sofosbuvir in combination with simeprevir, daclatasvir, and/or ribavirin. All patients were invited to participate in the study during the first interview. Adverse drug reactions were reported according to the treatment regimen and frequency of occurrence. Statistical analysis was used to compare adverse reactions between treatments and their associated factors.Results: A total of 405 patients were included in the study (mean age 59.6 ± 9.6 years); 61.0% were female, 88.1% were infected with genotype 1, and 65.4% were cirrhotic. The most prescribed treatment was the combination of sofosbuvir, daclatasvir, and ribavirin (55.3%). The majority of patients reported at least one ADR during treatment (83.2%), of which fatigue, anemia, and headache were the most common. Being female (OR = 1.86, [1.08‐3.20]) and use of ribavirin (OR: 2.39; 95% CI [1.38‐4.13]) were predictors for the development of ADR, which was also associated with development of anemia (OR: 10.28; 95% CI: [5.78‐18.30]). Treatment efficacy was 98.1%.Conclusions: Direct‐acting antiviral has been shown to be safe and effective. Therefore, use of ribavirin is questionable due to associated adverse reactions and similar efficacy to other treatments.